Alemtuzumab therapy reduces immunoglobulin levels in the peripheral blood and cerebrospinal fluid of people with relapsing-remitting multiple sclerosis.
Why this matters
This study provides Class IV evidence that long-term treatment with alemtuzumab can reduce immunoglobulin levels in relapsing-remitting multiple sclerosis. Prophylactic anti-infectives may be required, particularly in those receiving more than two treatment courses of alemtuzumab.
Vous souhaitez en lire plus ?
Connectez-vous à votre compte ou inscrivez-vous à Neurodiem pour consulter la suite.
Vous avez déjà un compte ? S'identifier
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.